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Introduction
Oxycodone is a strong, semi-synthetic opioid (1) that
has been in clinical use since 1917 for the treatment
of moderate-to-severe chronic pain (2). It has dem-
onstrated efﬁcacy in the treatment of postoperative,
osteoarthritis and cancer-related pain (1,3,4). Oxyco-
done is also effective in the treatment of the different
syndromes of neuropathic pain, such as diabetic neu-
ropathy (5,6) and postherpetic neuralgia (7).
The opioid-mediated side effects of opioid therapy
are well characterised and include respiratory depres-
sion, nausea, sedation, euphoria or dysphoria, consti-
pation and itching (8). Constipation is the most
frequently reported adverse event associated with
chronic opioid therapy (9). It is just one of a num-
ber of symptoms of opioid-induced bowel dysfunc-
tion (OBD), which can also include hard dry stools,
straining, bloating, abdominal cramping, distension
and increased gastric reﬂux (10). While many of the
side effects associated with opioid therapy resolve
with long-term use, no tolerance appears to occur
for constipation (8). The physical discomfort and
pain caused by constipation can force patients either
to discontinue their opioid therapy (11) or reduce
the opioid dose, resulting in inadequate pain control.
As a consequence, constipation is an important
adverse event that requires treatment.
Laxative regimens are established for clinical use
both for prophylaxis and treatment of opioid-induced
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SUMMARY
Background and objectives: Opioid-induced constipation can have a major neg-
ative impact on patients’ quality of life. This randomised clinical trial evaluated
patient assessment of the efﬁcacy and tolerability of oral prolonged-release (PR)
oxycodone when co-administered with oral naloxone PR. Methods: Two hundred
and two patients with chronic cancer- or non-cancer-related pain undergoing sta-
ble oxycodone PR therapy (40, 60 or 80 mg⁄day) were randomised to one of four
intervention groups: 10, 20 or 40 mg⁄day naloxone PR or placebo. Following a
4-week maintenance phase, patients were followed-up for 2 weeks in which time
they received oxycodone PR only. At the end of the maintenance phase, patients
and investigators were asked to assess treatment efﬁcacy and tolerability, as well
as preference for the titration or maintenance phase. Results: Patient and investi-
gator global assessment of efﬁcacy and tolerability improved with increasing nalox-
one dose. Efﬁcacy was ranked as ‘good’ or ‘very good’ by 50.0%, 67.4% and
72.5% of patients in the 10, 20 and 40 mg naloxone PR dose groups, respec-
tively, compared with 43.5% of patients in the placebo group. Patient assessment
of tolerability was similar between treatment groups and placebo, being ranked as
‘good’ or ‘very good’ by 83.3%, 79.1% and 82.5% of patients in the 10, 20 and
40 mg⁄day naloxone PR dose groups, respectively, compared with 71.7% of
patients in the placebo group. The maintenance treatment phase was preferred by
patients in the naloxone groups. A 2 : 1 dose ratio of oxycodone to naloxone was
also assessed. Efﬁcacy was ranked as ‘good’ or ‘very good’ by 70.4% of patients
treated with the 2 : 1 dose ratio compared with 43.5% of patients receiving pla-
cebo. Tolerability of the 2 : 1 dose ratio was ranked as being ‘good’ or ‘very
good’ by 81.5% of patients compared with 71.1% for the placebo group and
patients preferred the maintenance phase. Conclusions: The co-administration of
oral naloxone PR with oxycodone PR improves patient assessment of analgesic opi-
oid therapy for severe chronic pain, in terms of both efﬁcacy and tolerability.
What’s known
Constipation is the most commonly reported
adverse event associated with opioid use. Opioid-
induced constipation causes signiﬁcant discomfort,
severely affecting patients’ quality of life and
forcing patients either to discontinue their opioid
therapy or reduce opioid dose, resulting in
inadequate pain control.
What’s new
Co-administration of oral oxycodone PR and the
opioid antagonist oral naloxone PR provides
effective analgesia while reducing the symptoms of
opioid-induced constipation. Patient perception of
their analgesic therapy is improved by the
co-administration of oral oxycodone PR and
naloxone PR in terms of both efﬁcacy and
tolerability.
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do not affect the opioid receptor-mediated reason for
constipation, and are often ineffective (10,11).
The adverse effect of opioids on bowel function
stem largely from binding to opioid receptors in the
plexus myentericus and plexus submucosus of the
gut, while the analgesic effects are largely due to
l-opioid receptor binding in the central nervous
system (11,12). It should therefore be possible to
separate these two effects to provide analgesia with
reduced opioid-induced constipation.
Naloxone is a competitive (l, d and j) opioid
receptor antagonist that is mainly used intravenously
to reverse opioid overdose because of its high recep-
tor afﬁnity (13). Because of extensive ﬁrst-pass hepa-
tic metabolism, orally administered naloxone has
negligible systemic bioavailability of approximately
2% (14). At therapeutic oral doses, naloxone exerts
a local inhibitory effect on opioid action in the
gastrointestinal system without interfering with the
central nervous system. The administration of
oral naloxone may therefore reduce opioid-induced
constipation (and other aspects of OBD), while allow-
ing the centrally mediated analgesic effect of opioids.
A Phase II trial was conducted to assess the anal-
gesic efﬁcacy of prolonged-release (PR) oxycodone in
combination with orally administered naloxone PR
in patients with severe, chronic pain, and to evaluate
the efﬁcacy of the combination in improving bowel
function. One of the secondary endpoints of the trial
involved evaluating the patients’ and investigators’
preference for treatment. The analgesic efﬁcacy and
bowel function results of the trial have been pub-
lished separately. Co-administration of oxycodone
PR and naloxone PR provided effective analgesia
while signiﬁcantly reducing the symptoms of OBD
(15). The present paper reports the ﬁndings on
patient and investigator global assessment of efﬁcacy,
tolerability and treatment preference.
Methods
This was a multicentre, prospective, placebo-con-
trolled, randomised, double-blind, parallel-group
Phase II trial conducted in 28 centres in Germany
from May 2002 to April 2003. The study was con-
ducted in accordance with the Declaration of Hel-
sinki and its successors (Edinburgh 2000 and
Washington 2002) and complied with the principles
of Good Clinical Practice set by the International
Conference on Harmonization and applicable Ger-
man regulatory requirements. Written informed con-
sent was obtained from patients at screening.
Male and female patients aged 18 years and over
were eligible to enter the study if they had severe
cancer or non-cancer pain requiring opioid treat-
ment and⁄or insufﬁcient efﬁcacy or tolerability with
a WHO II or III analgesic, or were under stable oxy-
codone therapy (40–80 mg⁄day). Exclusion criteria
included current alcohol or drug abuse, severe car-
diovascular or respiratory disease, severe liver and
renal insufﬁciency and⁄or liver⁄renal carcinoma
and⁄or metastases. Patients were also excluded if
they had a history of paralytic ileus, psychoses or
Parkinson’s disease, current acute pancreatitis, were
taking early disease-related retirement, receiving opi-
oid treatment beside oxycodone, had a known hyper-
sensitivity to one of the study drugs, or had
participated in another clinical trial within 30 days.
Female patients who were of childbearing age, but
not adequately protected against conception, or who
were pregnant or lactating were also excluded.
The study consisted of three phases: a prerandomi-
sation phase; a maintenance phase in which double-
blind treatment was carried out; and a follow-up
phase (Figure 1). The study duration for each patient
was up to 10 weeks and six visits (V1–6) were
planned.
Following screening, patients entered either a titra-
tion or run-in period. Patients with inadequate pain
control entered the titration period and were titrated
and stabilised on a daily dose of oxycodone PR of
40, 60 or 80 mg. The starting oxycodone dose
depended on previous pain medication. Patients
already on stable oxycodone treatment with concom-
itant constipation, based on a clinical assessment
referred to need for laxative intake to have three
bowel movements per week, entered a 7-day run-in
period and were eligible to enter the maintenance
phase without prior titration. The oxycodone dose
could be adjusted at any time during the titration or
run-in period.
Patients who were receiving a stable oxycodone
dose every 12 h at the end of the titration⁄run-in
period, with no more than ﬁve rescue medication
administrations per week, and who needed regular
laxatives to have at least three bowel movements a
week were randomised to three naloxone treatment
groups or to placebo. Patients received their mainte-
nance dose of oxycodone (given in an open-label
fashion) plus a 10, 20 or 40 mg daily dose of nalox-
one PR or placebo (given in a double-blind manner)
every 12 h for 4 weeks. Patients were advised to stop
taking laxatives at the start of the maintenance phase,
although they could be restarted if no bowel move-
ments had occurred within 3 days. No dose adjust-
ments were allowed during the maintenance phase.
In the 2-week follow-up phase, patients received
their maintenance dose of oxycodone PR without
receiving naloxone PR.
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dose ratio for oxycodone PR and naloxone PR.
Within the three naloxone treatment groups, seven
active oxycodone⁄naloxone dose ratios were evalu-
ated (1 : 1, 1.5 : 1, 2 : 1, 3 : 1, 4 : 1, 6 : 1 and 8 : 1)
(Table 1). Based on the results of the analgesic efﬁ-
cacy and bowel function presented elsewhere, the
2 : 1 dose ratio was deemed the optimal ratio for
further development (15). For the global assessment,
only data for the 2 : 1 dose ratio compared with the
placebo group will be presented.
The study outcome was global assessment of efﬁ-
cacy, tolerability and preference assessed at the end
of the maintenance phase (V5). Safety assessments,
including physical examination, standard laboratory
tests and monitoring and recording of all adverse
events were performed at each visit.
Study assessments
Global assessment of efﬁcacy and tolerability was
completed at the end of the maintenance phase (V5)
and rated independently by the investigators and the
patients. The following rating scale was used:
one = very good; two = good; three = fairly good;
four = moderate; ﬁve = slightly poor; six = poor and
seven = very poor.
Preference for the maintenance phase (oxycodone
PR and naloxone PR) or the titration⁄run-in phase
(oxycodone only) regarding tolerability and efﬁcacy
of study medication was also assessed at the end of
the maintenance phase (V5). Preference was indi-
cated using the following scale: one = titration⁄run-
in; two = maintenance and three = no preference.
Statistical analysis
For the global assessment of efﬁcacy, tolerability and
preference (assessed by the investigator and by the
patient at the end of the maintenance phase), sum-
mary statistics for the 2 : 1 dose ratio of oxycodone
and naloxone compared with placebo and absolute
dose of naloxone were provided for the intention-to-
treat (ITT) population with non-missing values. The
percentages of patients rating the efﬁcacy or tolera-
bility of each treatment group as ‘good’ or ‘very
Figure 1 Study design. V = visit. Oxycodone and naloxone are prolonged-release formulations, and doses indicate daily
doses
Table 1 Dose ratios
Group 1 Group 2 Group 3 Group 4
Naloxone PR daily
dose (mg)
Placebo 5 + 5 10 + 10 20 + 20
Oxycodone PR
daily dose (mg)
2 · 20, 2 · 30, 2 · 40 2 · 20, 2 · 30, 2 · 40 2 · 20, 2 · 30, 2 · 40 2 · 20, 2 · 30, 2 · 40
Oxycodone
PR⁄naloxone
PR
Dose ratio
20⁄placebo
30⁄placebo
40⁄placebo
20⁄10, 60⁄10, 80⁄10
2 : 1, 6 : 1, 8 : 1
40⁄20, 60⁄20, 80⁄20
2:1 ,3:1 ,4:1
40⁄40, 60⁄40
80⁄40
1 : 1, 1.5 : 1, 2 : 1
In the placebo group, patients received oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone
PR 10, 20 or 40 mg⁄day. PR, prolonged-release.
Novel therapeutic approach for pain treatment 1161
ª 2008 Mundipharma Research GmbH & Co. KG
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, August 2008, 62, 8, 1159–1167good’ were combined to provide a composite posi-
tive score, while percentages for ‘moderate’, ‘slightly
poor’, ‘poor’ and very poor’ were combined to give a
negative score.
Results
A total of 230 patients were screened; 202 were sub-
sequently randomised and treated, and 166 com-
pleted the study. All randomised patients received
study medication and were included in the safety
population. The ITT population was deﬁned as all
randomised patients who received at least one dose
of naloxone or corresponding placebo and who had
at least one efﬁcacy assessment, and consisted of 196
(97.0%) patients.
All treatment groups and dose ratio groups were
well balanced in terms of demographics and baseline
characteristics. No relevant differences were observed
between treatment groups in terms of mean age,
race, mean weight, mean height and mean body mass
index. With regard to gender, 37.1% of patients in
the study were male.
Absolute naloxone PR dose
Patient global assessment of treatment efﬁcacy
improved with increasing naloxone PR dose. Efﬁcacy
was ranked as ‘good’ or ‘very good’ by 50.0%, 67.4%
and 72.5% of patients in the 10, 20 and 40 mg⁄day
naloxone PR dose groups respectively. In compari-
son, 43.5% of patients in the placebo group
described efﬁcacy as ‘good’ or ‘very good’ (Figure 2).
The 40 mg naloxone PR dose was ranked as ‘moder-
ate’ to ‘very poor’ by 17.5% of patients compared
with 43.5% of patients who received placebo.
This trend was mirrored by the investigators, with
54.8%, 67.4% and 70.0% ranking efﬁcacy for the 10,
20 and 40 mg⁄day naloxone PR dose groups as
‘good’ or ‘very good’ respectively (Figure 3). Efﬁcacy
of the placebo group was ranked as being ‘good’ or
‘very good’ by 47.8% of investigators.
Tolerability remained fairly stable with increasing
naloxone dose. The tolerability of the 10 mg⁄day
naloxone dose was ranked as ‘good’ or ‘very good’
by 83.3% of patients and investigators. The tolerabil-
ity of the 20 mg⁄day naloxone dose was ranked as
‘good’ or ‘very good’ by 79.1% of patients and
79.1% of investigators. The 40 mg⁄day naloxone
dose was ranked as ‘good’ or ‘very good’ by 82.5%
of patients and 85.0% of investigators in terms of
tolerability. This compared well with the tolerability
of the placebo group, which was ranked as ‘good’ or
‘very good’ by 71.7% of patients and 78.3% of inves-
tigators (Figures 4 and 5).
Figure 2 Patients’ global assessment of treatment efﬁcacy at the end of the maintenance phase – relative frequencies by
absolute naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received
oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg⁄day
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‘maintenance’ and ‘no preference’ was generally even
in terms of efﬁcacy for patients in the placebo group
– 37.0% of patients preferred the titration phase,
34.8% preferred the maintenance phase and 28.2%
had no preference. Patient preference for the mainte-
nance phase was 45.2%, 44.2% and 57.5% for the 10,
20 and 40 mg⁄day naloxone doses respectively (Fig-
ure 6). A similar trend towards preference for the
maintenance phase was also observed with investiga-
tors (Figure 7).
With regard to the preference of treatment phase
in terms of tolerability, a similar trend was observed.
In the placebo group, 34.8% of patients preferred the
maintenance phase compared with 54.8%, 60.5% and
57.5% of patients in the 10, 20 and 40 mg⁄day nal-
oxone groups respectively. A similar trend was seen
for investigators, with 34.8% preferring the mainte-
nance phase in the placebo group compared with
52.4%, 55.8% and 60.0% for the 10, 20 and 40 mg
naloxone groups respectively.
Oxycodone PR⁄naloxone PR dose ratio
In terms of efﬁcacy, the 2 : 1 dose ratio was ranked
‘good’ or ‘very good’ by 70.4% of patients and inves-
tigators. In comparison, placebo (40, 60 and
80 mg⁄placebo combined) was ranked as ‘good’ or
‘very good’ by 43.5% of patients and 47.8% of inves-
tigators. Only 18.5% of patients and 11.1% of inves-
tigators ranked the efﬁcacy of the 2 : 1 dose ratio as
‘moderate’, ‘slightly poor’, ‘poor’ or ‘very poor’ com-
pared with 37.0% and 43.5%, respectively, for pla-
cebo.
In terms of tolerability, the 2 : 1 dose ratio was
ranked ‘good’ or ‘very good’ by 81.5% of patients
and investigators. This compares favourably with pla-
cebo (40, 60 and 80 mg⁄placebo combined), which
was ranked as ‘good’ or ‘very good’ by 78.3% of
investigators and 71.7% of patients. None of the
investigators and only 7.4% of patients ranked the
tolerability of the 2 : 1 dose ratio as ‘moderate’ to
‘very poor’ compared with 13.0% and 17.4%, respec-
tively, for placebo.
With regard to patient preference for treatment
phase based on efﬁcacy, the data for placebo were
evenly distributed between the different study
phases (titration phase 37.0%; maintenance phase
34.8%; no preference 28.3%). In contrast, the
majority of patients in the treatment arm of the
study preferred the maintenance phase in which
they received oxycodone PR and naloxone PR. For
the 2 : 1 dose ratio, 51.9% of patients preferred the
maintenance phase, while 33.3% had no preference.
A similar trend was seen for investigators, with
48.1% preferring the maintenance phase in the
2 : 1 dose ratio group compared with 30.4% who
preferred the maintenance phase for the placebo
group.
Figure 3 Investigators’ global assessment of treatment efﬁcacy at the end of the maintenance phase – relative frequencies
by absolute naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received
oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg⁄day
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absolute naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received
oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg⁄day
Figure 5 Investigators’ global assessment of treatment tolerability at the end of the maintenance phase – relative
frequencies by absolute naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group,
patients received oxycodone PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20
or 40 mg⁄day
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ferent treatment phases in the placebo group was
also evenly distributed in terms of tolerability (titra-
tion phase 32.6%; maintenance phase 34.8%; no
preference 32.6%). For the 2 : 1 dose ratio, 55.6% of
patients preferred the maintenance phase, while
29.6% had no preference. A similar trend was seen
for investigators, with 34.8% preferring the mainte-
Figure 7 Investigators’ preference of treatment efﬁcacy according to study phase – relative frequencies by absolute
naloxone prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received oxycodone
PR and a placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg⁄day
Figure 6 Patients’ preference of treatment efﬁcacy according to study phase – relative frequencies by absolute naloxone
prolonged-release (PR) dose (intention-to-treat population). In the placebo group, patients received oxycodone PR and a
placebo. Whereas treatment groups received oxycodone PR plus naloxone PR 10, 20 or 40 mg⁄day
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55.6% for the 2 : 1 dose ratio.
The safety analysis included a total of 202 patients.
No trends or possible treatment-related pathological
laboratory ﬁndings could be identiﬁed for any of the
treatment groups. No deaths occurred during the
study.
Adverse events during the maintenance phase were
observed in all treatment groups (range: 62.7–
70.0%), although the number of events increased
with increasing naloxone PR dose, with 111, 119,
129 and 140 events in the placebo, 10, 20 and
40 mg⁄day naloxone PR dose groups respectively.
Most adverse events were deemed to be mild or
moderate in intensity based on investigator assess-
ment. There was a slight trend for an increase in
moderate and severe adverse events with increasing
naloxone dose, but the incidence of serious adverse
events was low and generally comparable across all
active naloxone PR treatment groups. The most fre-
quent adverse events were increased sweating, diar-
rhoea, nausea, abdominal pain, restlessness, muscle
cramps, sedation, headache and vertigo.
Discussion
The results from this clinical trial demonstrate that,
in terms of patient assessment, the co-administration
of oxycodone PR and naloxone PR is effective for
the treatment of patients with severe chronic pain,
whether cancer related or not. The study also indi-
cates that increased naloxone PR dose (10, 20 or
40 mg⁄day) is associated with superior ratings of
global assessment of efﬁcacy and preference for treat-
ment. Tolerability was similar for all doses of nalox-
one PR and placebo, indicating that the addition of
naloxone does not cause further unwanted effects.
While bowel function is classically seen as an issue
related to opioid tolerability, in this study patients
viewed the improvements in bowel function as part
of the efﬁcacy of the combination of oxycodone PR
and naloxone PR.
The global assessment of preference shows that
more patients preferred treatment during the main-
tenance phase, which consisted of the combination
of naloxone PR and oxycodone PR, rather than the
titration⁄run-in phase, which consisted of oxyco-
done PR only. This ﬁnding was mirrored by the
investigators’ rating, which also showed a preference
for maintenance phase of the study. In the oxyco-
done PR⁄placebo group, patient preference was rela-
tively evenly distributed between the three response
groups – maintenance phase, titration phase, no
preference – and there was no overall preference for
a speciﬁc response for either efﬁcacy or tolerability.
Again, this result was mirrored by the investigators’
assessment.
In conclusion, the addition of naloxone PR to
oxycodone PR improves patient assessment of their
analgesic therapy. This is especially signiﬁcant for
tolerability, where the stability of the patient prefer-
ence across increasing naloxone dose indicates that
the addition of naloxone to oxycodone does not
result in any additional side effects. These results
from the global assessment are conﬁrmed by other
results from this study presented elsewhere, which
showed no impact of naloxone PR on the analgesic
efﬁcacy of oxycodone PR, with improvements in
bowel function and reduced laxative intake (15).
Prevention of opioid-induced constipation is con-
sidered a more effective therapeutic strategy than
treatment (11). The co-administration of oxycodone
PR and naloxone PR has been shown to signiﬁcantly
reduce the impact of opioid-induced constipation,
with dose-dependent increases in stool frequency and
dose-dependent decreases in the use of laxatives (15).
Given the efﬁcacy of oxycodone PR in a number
of different pain syndromes, the addition of nalox-
one PR to prevent or reduce opioid-induced consti-
pation can be of potential beneﬁt to a signiﬁcant
number of patients suffering from chronic pain,
allowing them to receive analgesia on a long-term
basis and consequently to improve their quality of
life. Indeed, the potential beneﬁt of the oxycodone
PR⁄naloxone PR combination is apparent by the
patients’ preference for treatment during the mainte-
nance phase during which they received both oxyco-
done PR and naloxone PR. Given the improvement
in bowel function – and consequently quality of life
– with the use of the oxycodone PR⁄naloxone PR
combination, the management of severe, chronic
pain will be facilitated for patients and physicians
alike.
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